We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.
BLCM

Delisted

BLCM was delisted on the 1st of June, 2023.

Back to rankings

4 hedge funds and large institutions have $173K invested in Bellicum Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% less capital invested

Capital invested by funds: $470K → $173K (-$297K)

84% less funds holding

Funds holding: 25 → 4 (-21)

91% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 23

Holders
4
Holders Change
-21
Holders Change %
-84%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$243K
2
BRWA
B. Riley Wealth Advisors
Florida
+$6.16K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$148K
2
LFCM
Long Focus Capital Management
Puerto Rico
-$108K
3
BBA
Baker Bros. Advisors
New York
-$82.2K
4
BlackRock
BlackRock
New York
-$25K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$24K

BLCM Hedge Fund Activity: Q2 2023 in Review

4 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2023, worth a combined $173K — down 63% from $470K a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of BLCM and 2 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Boxer Capital, opening a new position worth an estimated $243K. The largest seller was Ikarian Capital, exiting entirely with an estimated $148K sold.

  • 4 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2023, down from 25 in Q1 2023.
  • Funds reported $173K of Bellicum Pharmaceuticals, Inc. stock for Q2 2023, down 63% quarter-over-quarter.
  • 2 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2023 and 23 closed out, a net change of -21 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2023 was Boxer Capital, an estimated $243K added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2023 was Ikarian Capital, an estimated $148K sold.

Based on aggregated 13F filings for Q2 2023.